​

​

Three Months Ended June 30,

​

Six Months Ended June 30, 

​

​

2026

​

2025

​

2026

​

2025

Grant and award revenue

​

$

2,510

​

$

2,169

​

$

3,299

​

$

2,660

Operating expenses

​

​

​

​

​

​

​

​

​

​

​

​

Research and development expenses:

​

​

​

​

​

​

​

​

​

​

​

​

AP-PA02: Non-Cystic Fibrosis Bronchiectasis

​

​

16

​

​

152

​

​

(10)

​

​

(288)

AP-PA02: Cystic Fibrosis

​

​

8

​

​

14

​

​

8

​

​

25

AP-SA02: Bacteremia

​

​

426

​

​

1,011

​

​

541

​

​

1,663

AP-SA02: Prosthetic Joint Infection

​

​

-

​

​

1

​

​

-

​

​

2

Expenses not allocated by projects

​

​

839

​

​

592

​

​

1,733

​

​

1,112

Total external research and development expenses

​

​

1,289

​

​

1,770

​

​

2,272

​

​

2,514

Research and development personnel expenses

​

​

3,535

​

​

2,293

​

​

6,160

​

​

4,606

Other research and development expenses

​

​

2,762

​

​

2,331

​

​

5,265

​

​

4,703

Total research and development expenses

​

​

7,586

​

​

6,394

​

​

13,697

​

​

11,823

General and administrative expenses:

​

​

​

​

​

​

​

​

​

​

​

​

General and administrative personnel expenses

​

​

3,045

​

​

1,191

​

​

4,507

​

​

2,592

Other general and administrative expenses

​

​

2,191

​

​

1,428

​

​

4,192

​

​

3,280

Total general and administrative expenses

​

​

5,236

​

​

2,619

​

​

8,699

​

​

5,872

Total operating expenses

​

​

12,822

​

​

9,013

​

​

22,396

​

​

17,695

Operating loss

​

​

(10,312)

​

​

(6,844)

​

​

(19,097)

​

​

(15,035)

Other income (expense), net

​

​

84,453

​

​

(9,451)

​

​

(22,108)

​

​

(7,791)

Net income (loss)

​

$

74,141

​

$

(16,295)

​

$

(41,205)

​

$

(22,826)